Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Biohit

2.13 EUR0.00 %21.10. klo 13.36
4,991 following

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
0.00 %
-12.70 %
-25.26 %
-11.25 %
-42.28 %
-29.93 %
+7.58 %
+8.40 %
-59.04 %

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more
Market cap
32.39M EUR
Turnover
5.7K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
06.08.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
A new CEO blog post was published by Biohit today: Biohit Biohit - IR-blogi Biohit Oyj on vuonna 1988 perustettu globaaleilla markkinoilla toimiva suomalainen bioteknologiayritys.
10/14/2026, 12:46 PM
by Antti Siltanen
9
Here are Antti’s comments on Biohit publishing a scientific review that discusses a two-stage strategy for preventing stomach cancer using GastroPanel and Acetium products. Inderes – 10 Sep 26 Biohit: Uusi katsaus yhdistää avaintuotteet hoitopoluksi - Inderes Uusi artikkeli kytkee...
9/10/2026, 5:01 AM
by Sijoittaja-alokas
7
Nasdaq Company News Uusi tieteellinen katsaus tukee biomarkkereihin perustuvaa mahasyöpäriskin... New scientific review supports biomarker-based assessment of gastric cancer risk and determination of the need for gastroscopy
9/3/2026, 9:02 AM
by Ashwanga
6
Biohit has dropped rapidly to roughly the level it was at 3 years ago. I find this quite strange considering how the company’s numbers are developing (the image shows figures up to 2025; in H1 2025 the pace continued to improve, and guidance points to growth in both the short and...
3 hours ago
by Puutaheinää
4
And here are Antti’s latest comments on Biohit Biohit published the CEO’s Q3 blog post on Wednesday, which provided a qualitative review of the progress of the company’s strategic initiatives without new financial figures. In our view, the review reflects the slow sales cycle typical...
10/15/2026, 5:12 AM
by Sijoittaja-alokas
4
Syrjänen is just under 80 years old, so there’s hardly any shadowy mysticism related to Biohit here, and I’m not going to guess what personal reasons there might be. Anyone can create scenarios for the background.
9/2/2026, 8:56 PM
by Tunturisusi
4
Isn’t there some vague, really massive share issue authorization “in the pipeline” that at least no retail investor knows what it’s going to be used for and who it will actually benefit?
3 hours ago
by Ehemot
1
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 06.08.2026

Latest extensive report

Released: 15.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Biohit Q3'26: Strategic projects are progressing moderately as expected
Analyst Comment15.10.2026 klo 09.15 by
Antti Siltanen

Biohit Q3'26: Strategic projects are progressing moderately as expected

The GastroPanel test is being piloted in the UK to shorten waiting lists.

Biohit
Biohit: New review combines key products into a care pathway
Analyst Comment10.09.2026 klo 08.46 by
Antti Siltanen

Biohit: New review combines key products into a care pathway

A new article links Acetium as part of GastroPanel testing and supports the commercialization of the product.

Biohit
Press release03.09.2026 klo 12.00

New scientific review supports non-invasive biomarker-based triage for gastric cancer risk

Biohit

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release02.09.2026 klo 17.00

Biohit Oyj: Kari Syrjänen resigns as Chair of the Board of Directors

Biohit
Biohit: GastroPanel Quick Test also works during proton pump inhibitor therapy
Analyst Comment19.08.2026 klo 09.27 by
Antti Siltanen

Biohit: GastroPanel Quick Test also works during proton pump inhibitor therapy

Proton pump inhibitors do not affect the accuracy of the GastroPanel Quick Test.

Biohit
Biohit H1'26: Strong earnings clouded by weak cash flow
Research06.08.2026 klo 10.50 by
Antti Siltanen

Biohit H1'26: Strong earnings clouded by weak cash flow

Biohit's reported earnings were excellent, but cash flowed out of the company in the first half of the year.

Biohit
Regulatory press release05.08.2026 klo 09.30

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2026 (unaudited) 

Biohit
Biohit H1'26 preview: Moderate growth against weak comparison period
Analyst Comment31.07.2026 klo 08.23 by
Antti Siltanen

Biohit H1'26 preview: Moderate growth against weak comparison period

Chile's screening program accelerates revenue growth to 8% in our H1 estimate.

Biohit
Biohit: Sold on summer sale
Research29.06.2026 klo 09.00 by
Antti Siltanen

Biohit: Sold on summer sale

The stock's valuation has fallen to a rather low level.

Biohit
Regulatory press release05.06.2026 klo 18.00

Constitutive meeting of Biohit Oyj’s Board of Directors

Biohit
Regulatory press release03.06.2026 klo 18.00

Decisions of the Annual General Meeting of Biohit Oyj

Biohit
Regulatory press release06.05.2026 klo 15.45

Correction: Notice of Biohit Oyj’s Annual General Meeting

Biohit
Regulatory press release06.05.2026 klo 15.06

Notice of Biohit Oyj’s Annual General Meeting

Biohit
Regulatory press release06.05.2026 klo 15.00

Notice of Biohit Oyj’s Annual General Meeting

Biohit
Study: Biohit's GastroPanel reduced waiting lists
Analyst Comment22.04.2026 klo 08.26 by
Antti Siltanen

Study: Biohit's GastroPanel reduced waiting lists

Endoscopy wait times were reduced by 87%.

Biohit
Press release21.04.2026 klo 14.00

A peer-reviewed study confirms the value of the GastroPanel® test in reducing endoscopy waiting lists

Biohit
Regulatory press release01.04.2026 klo 14.00

Biohit Plc B-shares Subscribed with Stock Options I 2021D

Biohit
US market roadmap for medical devices – a European perspective
Analyst Comment27.03.2026 klo 12.45 by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release18.03.2026 klo 09.30

Publication of Biohit Oyj Annual Report 2025

Biohit
Regulatory press release18.03.2026 klo 09.30

Publication of Biohit Oyj Remuneration Report 2025

Biohit